The number of employees laid off and companies letting people go increased year over year during the first half of 2025. BioSpace recaps the five largest layoff rounds, including cuts at Bayer, BMS ...

Biogen expects to record a $46 million expense as part of its second quarter earnings. The Cambridge, Mass., biotechnology company said Monday the expense is an in-process research and development, ...

Assessing the distribution of a medication in the brain is critical for the treatment of a vast range of neurological ...

CAMBRIDGE, MA, USA I June 30, 2025 I Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, PROMINENT. The Phase 3 ...

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SP ...

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who ...

The problems cut across the industry as a whole. Many publicly traded biotech companies are now valued at less than the cash ...

Detailed price information for Ionis Pharmaceuticals (IONS-Q) from The Globe and Mail including charting and trades.

Biogen Inc on Wednesday said it had cinched a $900 million deal to resolve a whistleblower lawsuit accusing the biotech company of paying doctors kickbacks to ...

Biogen, based in Cambridge, Massachusetts, makes blockbuster multiple sclerosis treatments Avonex and Tecfidera, with $3.1 billion and $2.9 billion in revenue in 2014, respectively.

Biogen, based in Cambridge, Massachusetts, makes blockbuster multiple sclerosis treatments Avonex and Tecfidera, with $3.1 billion and $2.9 billion in revenue in 2014, respectively.

Biogen Idec of Cambridge, Massachusetts, will expand its neuropathic pain portfolio with the purchase of Convergence Pharmaceuticals of Cambridge, UK. Biogen Idec will pay $200 million upfront and ...